ERBB receptor inhibitors

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein,
• R1 is hydrogen;
• R2 is C1-3 alkyl;
• G is N;
• W is O or S;
• Y is bond or C1-3 alkylene;
• R3 is 3-10 membered saturated or unsaturated carbocyclyl, or 3-10 membered saturated or unsaturated heterocyclyl which can be optionally mono- or independently multi-substituted by deuterium, halogen, hydroxyl, amino, C1-12 alkyl, C1-12 alkoxyl, C1-12 alky-OH, C1-12 haloalkyl, substituted C1-12 alkyl;
• i is 0, 1, 2 or 3, and
• each R4 is independently deuterium, halogen, amino, hydroxyl, C1-12 alkyl, C1-12 alkoxyl, C1-12 alky-OH, or C1-12 haloalkyl;
• j is 0, 1, 2 or 3, and
• each R5 is independently halogen, amino, hydroxyl, C1-12 alkyl, C1-12 alkoxyl, C1-12 alky-OH, C1-12 haloalkyl or OR6, which can be optionally mono- or independently multi-substituted by;
• R6 is 3-10 membered saturated or unsaturated carbocyclyl, or 3-10 membered saturated or unsaturated heterocyclyl optionally mono- or independently multi-substituted by hydroxyl, halogen, cyano, C1-12 alkyl, or C1-12 haloalkyl;
• A is O or S;
• E is
• X1, X2, X3, and X4 are each independently N or CR8;
• X5 and X6 are each independently N or CR8, and X7 is O, S, NR9 or CR10R11, wherein at least one of X5 and X6 is N;
• R8, R9, R10, and R11 are each independently hydrogen, halogen, C1-12 alkyl, cyano, amino, hydroxyl, C1-12 alkoxyl, C1-12 alky-OH, or C1-12 haloalkyl;
• p is 0, 1, 2 or 3, and
• each R7 is independently halogen, amino, hydroxyl, C1-12 alkyl, C1-12 alkoxyl, C1-12 alky-OH, or C1-12 haloalkyl.